Nature Communications (Jan 2020)
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist
- Giulia Parisi,
- Justin D. Saco,
- Felix B. Salazar,
- Jennifer Tsoi,
- Paige Krystofinski,
- Cristina Puig-Saus,
- Ruixue Zhang,
- Jing Zhou,
- Gardenia C. Cheung-Lau,
- Alejandro J. Garcia,
- Catherine S. Grasso,
- Richard Tavaré,
- Siwen Hu-Lieskovan,
- Sean Mackay,
- Jonathan Zalevsky,
- Chantale Bernatchez,
- Adi Diab,
- Anna M. Wu,
- Begoña Comin-Anduix,
- Deborah Charych,
- Antoni Ribas
Affiliations
- Giulia Parisi
- Department of Medicine, David Geffen School of Medicine at UCLA
- Justin D. Saco
- Department of Medicine, David Geffen School of Medicine at UCLA
- Felix B. Salazar
- Department of Medical and Molecular Pharmacology, David Geffen School of Medicine at UCLA
- Jennifer Tsoi
- Department of Medicine, David Geffen School of Medicine at UCLA
- Paige Krystofinski
- Department of Medicine, David Geffen School of Medicine at UCLA
- Cristina Puig-Saus
- Department of Medicine, David Geffen School of Medicine at UCLA
- Ruixue Zhang
- Department of Medicine, David Geffen School of Medicine at UCLA
- Jing Zhou
- Isoplexis Corporation
- Gardenia C. Cheung-Lau
- Department of Surgery, David Geffen School of Medicine at UCLA
- Alejandro J. Garcia
- Department of Medicine, David Geffen School of Medicine at UCLA
- Catherine S. Grasso
- Department of Medicine, David Geffen School of Medicine at UCLA
- Richard Tavaré
- Regeneron Pharmaceuticals, Inc.
- Siwen Hu-Lieskovan
- Department of Medicine, David Geffen School of Medicine at UCLA
- Sean Mackay
- Isoplexis Corporation
- Jonathan Zalevsky
- Nektar Therapeutics
- Chantale Bernatchez
- Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
- Adi Diab
- Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
- Anna M. Wu
- Department of Medical and Molecular Pharmacology, David Geffen School of Medicine at UCLA
- Begoña Comin-Anduix
- Department of Surgery, David Geffen School of Medicine at UCLA
- Deborah Charych
- Nektar Therapeutics
- Antoni Ribas
- Department of Medicine, David Geffen School of Medicine at UCLA
- DOI
- https://doi.org/10.1038/s41467-019-12901-3
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Adoptive cell transfer (ACT) of T cells for tumor treatment often requires IL-2 administration. Here, the authors show that a modified IL-2 cytokine (NKTR-214) can outperform IL-2 in a melanoma mouse model.
